In the first segment of this one-on-one interview series, Peter Salgo, MD, and Irwin W. Tischler, DO, discuss major innovations in the treatment of cancer. Drs Salgo and Tischler also discuss the 21st Century Cures initiative recently launched by the US Congress.
Dr Tischler, a national medical director of oncology for Cigna, says that the use of molecular profiling and targeted therapy have been a “tremendous boon” in the treatment of cancer over the past decade. Targeted therapies make possible the personalization of treatment based on specific genetic abnormalities and are also associated with a lower incidence of side effects.
Next, Drs Salgo and Tischler discuss the 21st Century Cures initiative, recently launched by the US Congress. It is expected that this initiative will help address various barriers to the development of new treatment options.
The initiative is designed to allow various stakeholders in healthcare to share their opinions about how to accelerate the pace of healthcare innovation in the United States, Dr Tischler remarks. The initiative is attempting to eliminate regulatory barriers that have impeded innovation in the past. Use of a comprehensive team approach is expected to help launch new drugs and devices in a more timely fashion.
Dr Tischler predicts that there will be a rapid acceleration of the pace of innovation, especially if the initiative helps lower the costs that are currently associated with research and development by pharmaceutical companies.
Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Watch our related Peer Exchange,
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Covered Preventive Services at Risk: V-BID Summit Breaks Down the Braidwood v Becerra Case
March 20th 2024For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More
Fragmented Payer System, Vulnerable Supply Chain Among Threats to Accessing Essential Medicines
March 13th 2024During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.
Read More